Home › Funds › Siren, L.L.C. › DYN
Siren, L.L.C. position in DYN
Dyne Therapeutics, Inc. · Health Care
Siren, L.L.C. reported holding 2,429,125 shares of DYN (Dyne Therapeutics, Inc.) in its Q3 2026 13F filing — a position valued at US$39.1M, representing 0.93% of its reported portfolio and ranking #30 among its reported holdings. Siren, L.L.C. has disclosed DYN holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Siren, L.L.C.'s DYN position evolved
Siren, L.L.C. first disclosed a stake in DYN in Q3 2024 at 1,134,664 shares (US$40.8M). The position peaked in Q4 2025 at 3,502,941 shares, worth US$68.5M. Across 9 filings, Siren, L.L.C. increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,429,125 shares valued at US$39.1M — an increase of 300,000 shares quarter over quarter.. Notable position changes include a 102% increase in Q1 2025 (shares fell 9% over the following quarter), a 78% increase in Q2 2025 (shares rose 33% over the following quarter), a 36% trim in Q1 2026 (shares rose 23% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 1.13M | $40.76M | New |
| Q4 2024 | 1.35M | $31.75M | Add |
| Q1 2025 | 2.72M | $28.43M | Add |
| Q2 2025 | 4.84M | $46.04M | Add |
| Q3 2025 | 4.73M | $59.82M | Reduce |
| Q4 2025 | 3.50M | $68.52M | Reduce |
| Q1 2026 | 2.23M | $40.41M | Reduce |
| Q2 2026 | 2.13M | $47.29M | Reduce |
| Q3 2026 | 2.43M | $39.13M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DYN and 13F data
DYN (Dyne Therapeutics, Inc.) is a Health Care company. 41 other funds we track also report a position in DYN — the largest reported positions include Atlas Venture Life Science Advisors, LLC (US$151.0M), TCG Crossover Management, LLC (US$102.5M), FCPM III SERVICES B.V. (US$85.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DYN
- Atlas Venture Life Science Advisors, LLC 6.80M sh · $151.03M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $102.50M · Q2 2026
- FCPM III SERVICES B.V. 3.85M sh · $85.47M · Q2 2026
- Vestal Point Capital, LP 3.38M sh · $74.96M · Q2 2026
- ORBIMED ADVISORS LLC 3.24M sh · $71.86M · Q2 2026
- Frazier Life Sciences Management, L.P. 3.15M sh · $70.03M · Q2 2026
- ARMISTICE CAPITAL, LLC 3.09M sh · $68.57M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.69M sh · $59.73M · Q2 2026
- Logos Global Management LP 2.55M sh · $56.64M · Q2 2026
- Venrock Adviser, LLC 2.17M sh · $48.28M · Q2 2026
- MPM BioImpact LLC 1.92M sh · $42.69M · Q2 2026
- SAMLYN CAPITAL, LLC 1.75M sh · $38.97M · Q2 2026
More on Siren, L.L.C.
FAQ
How long has Siren, L.L.C. held DYN?
Siren, L.L.C. has disclosed DYN holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Siren, L.L.C.'s current position in DYN?
As of Q3 2026, Siren, L.L.C. holds 2.43M shares of DYN (Dyne Therapeutics, Inc.), valued at $39.13M, representing 0.93% of its reported portfolio and ranking #30.
Has Siren, L.L.C. been buying or selling DYN?
In the latest 13F filing (Q3 2026), Siren, L.L.C. increased its position in DYN. The position peaked in Q4 2025 at 3.50M shares.
Which other funds hold DYN?
Other major institutional holders of DYN include Atlas Venture Life Science Advisors, LLC, TCG Crossover Management, LLC, FCPM III SERVICES B.V., among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.